Tirzepatide for Alcohol Use Disorder
NCT06994338
Not Yet Recruiting
The objective of this Phase 2 randomized controlled trial is to evaluate the effects of weekly tirzepatide (vs. placebo) on alcohol consumption and cardiometabolic outcomes in adults with alcohol use disorder and overweight or obesity.
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
05/24/2025
Locations: Keck School of Medicine, University of Southern California, Los Angeles, California
Conditions: Alcohol Use Disorder, Obesity and Overweight
Register for Updates
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
NCT06643728
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/23/2025
Locations: Pinnacle Research Group, LLC, Anniston, Alabama +11 locations
Conditions: Obesity, Overweight
Register for Updates
Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction
NCT06914141
Active Not Recruiting
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/21/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
Register for Updates
Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data
NCT06914154
Active Not Recruiting
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
05/21/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Diabetes Mellitus, Type 2, Heart Failure With Preserved Ejection Fraction (HFPEF)
Register for Updates
Study of Tirzepatide for Recovery and Alcohol Use Management
NCT06727331
Not Yet Recruiting
This is a pilot, 4-week, double-blind, placebo-controlled, randomized trial of individuals with alcohol use disorder (AUD) to receive weekly injections of either tirzepatide (n=10) or matching placebo (n=10). The primary aim is to determine the effects of tirzepatide on cue-reactivity among individuals with AUD. The secondary aim is to assess the safety and preliminary efficacy of tirzepatide for AUD.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Alcohol Use Disorder (AUD)
Register for Updates
Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction
NCT06980623
Active Not Recruiting
This cohort study aims to assess the comparative effectiveness of tirzepatide versus semaglutide with respect to cardiovascular events in patients with type 2 diabetes and heart failure with preserved ejection fraction.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Type 2 Diabetes, Heart Failure
Register for Updates
Tirzepatide in PWS, HO and GNSO
NCT06901245
Recruiting
This research study is comparing the effectiveness of a weight loss medication called Tirzepatide in young adults with Prader-Willi Syndrome and/or hypothalamic obesity, as compared to young adults with obesity that is unrelated to a genetic syndrome or underlying medical cause. These groups will be given medication for 1 year to see how weight and other health factors are effected by the medication.
Gender:
ALL
Ages:
Between 18 years and 26 years
Trial Updated:
05/14/2025
Locations: Children's Minnesota, Minneapolis, Minnesota +2 locations
Conditions: Prader-Willi Syndrome, Hypothalamic Obesity, Obesity/Therapy
Register for Updates
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
NCT06131437
Active Not Recruiting
This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide. CagriSema is not yet being prescribed by doctors. Participant will get injections once a week throughout the treatment period. Participant will inject the study medicine under the skin with a pen injector in the thigh, stomach, or upper arm. After a first low dose, the study medic... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: Univ of Alabama Birmingham, Birmingham, Alabama +44 locations
Conditions: Obesity
Register for Updates
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
NCT06582875
Recruiting
The proposed clinical trial aims to assess if a year of treatment with a glucagon-like peptide 1 receptor agonist, a medication approved for weight management that also improves the body's response to glucose and insulin, can slow kidney growth in adults with autosomal dominant polycystic kidney disease who are overweight or obese. The study will also evaluate changes in abdominal fat and kidney metabolism using cutting-edge images techniques. Blood and urine samples will provide further insight... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/05/2025
Locations: University of Colorado - Anschutz Medical Campus, Aurora, Colorado
Conditions: Autosomal Dominant Polycystic Kidney, Obesity
Register for Updates
2024 Tirzepatide-Bariatric Surgery
NCT06721507
Recruiting
This clinical trial will test whether preoperative tirzepatide treatment improves outcomes after bariatric surgery. The outcome of this study could impact therapeutic guidelines for the multimodal treatment of obesity. The major objectives are: 1. To evaluate whether pre-operative tirzepatide treatment reduces tissue and circulating inflammatory markers at the time of surgery. 2. To establish the relationship of these changes with postoperative improvements in weight loss, metabolic and inflam... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Obesity and Obesity-related Medical Conditions, Bariatric Surgery
Register for Updates
Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients
NCT06774079
Recruiting
The purpose of this study is to use diet and an injectable medication called tirzepatide (Zepbound) glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist (GIP-GLP-1 RA) medication as adjunctive therapy (another treatment used together with the primary treatment) for Crohn's disease patients with mild disease who are on stable doses of biologic medication (infliximab or adalimumab) and who have a body mass index (BMI) of at least 27.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: University of Miami, Miami, Florida
Conditions: Crohn Disease
Register for Updates
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
NCT06662383
Active Not Recruiting
The main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Medical Advancement Centers of Arizona, Tempe, Arizona +64 locations
Conditions: Obesity
Register for Updates